| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK- | Nürtingen, Stuttgart, München | Phase III | rekrutiert |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Nürtingen, Heinsberg | Phase II | rekrutiert |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinica | Nürtingen, Waldshut-Tiengen, Mannheim | Phase II | rekrutiert |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men | Augsburg, Berlin, Braunschweig | Phase III | rekrutiert |
| Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Aachen, Augsburg, Essen | Phase I / Phase II | rekrutiert |
| Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer | Stuttgart, Homburg | ohne Phasenangabe | rekrutiert |
| Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap) | Düsseldorf | — | rekrutiert |
| Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostat | Dresden, Düsseldorf, Gronau | Phase III | rekrutiert |
| Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s) | Hamburg | ohne Phasenangabe | rekrutiert |
| European Registry of Next Generation Imaging in Advanced Prostate Cancer | Bonn, Hamburg, München | — | rekrutiert |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Essen, Hamburg | Phase I | rekrutiert |
| Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac | Tübingen | ohne Phasenangabe | rekrutiert |
| Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial | Erlangen | Phase II | rekrutiert |
| Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III) | Frankfurt am Main, München, Kiel | ohne Phasenangabe | rekrutiert |
| Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Ster | Freiburg im Breisgau | ohne Phasenangabe | rekrutiert |
| Liquid Biopsy Under PSMA Radioligand Therapy | Augsburg, München, Würzburg | — | rekrutiert |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Essen, München, Rostock | Phase IV | rekrutiert |
| Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) | Berlin | — | rekrutiert |
| PROCARE - PROstate Cancer Real World Evidence Registry | Freiburg im Breisgau, Heidelberg, Mannheim | — | rekrutiert |
| PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer | Essen | — | rekrutiert |
| Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | Köln, Rostock | Phase I / Phase II | rekrutiert |
| Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies | Heidelberg | ohne Phasenangabe | rekrutiert |
| Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer | Chemnitz, Düsseldorf, Hamburg | Phase II | rekrutiert |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Essen, Heidelberg, München | Phase I | rekrutiert |
| Study of MR-based IGRT for Prostate Cancer | Tübingen | ohne Phasenangabe | rekrutiert |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation | Heidelberg, Augsburg, Hamburg | Phase I / Phase II | rekrutiert |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Stud | Tübingen | — | rekrutiert |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-0682 | Heidelberg, Nürtingen, Tübingen | Phase III | rekrutiert |
| Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer | Jena | — | rekrutiert |